PART IV. Cytokine and Hormone ImmunotherapyTreatment of AIDS-Related Kaposi's Sarcoma with Interleukin-12: Rationale and Preliminary Evidence of Clinical Activity

التفاصيل البيبلوغرافية
العنوان: PART IV. Cytokine and Hormone ImmunotherapyTreatment of AIDS-Related Kaposi's Sarcoma with Interleukin-12: Rationale and Preliminary Evidence of Clinical Activity
المؤلفون: James M. Pluda, Giovanna Tosato, Kathleen M. Wyvill, Seth M. Steinberg, Isaac R. Rodriguez-Chavez, Robert Yarchoan, Andrew T. Catanzaro, Richard F. Little, Karen Aleman
المصدر: Critical Reviews™ in Immunology. 27:401-414
بيانات النشر: Begell House, 2007.
سنة النشر: 2007
مصطلحات موضوعية: Polymers and Plastics, medicine.medical_treatment, AIDS-Related Opportunistic Infections, Context (language use), Immunotherapy, Biology, medicine.disease_cause, medicine.disease, Cytokine, Immunology, medicine, Cancer research, Doxorubicin, Interferon gamma, Sarcoma, Kaposi's sarcoma-associated herpesvirus, General Environmental Science, medicine.drug
الوصف: In this article, we review the preliminary evidence for the activity of interleukin-12 (IL-12) against Kaposi's sarcoma (KS) and discuss these results in the context of the biology of IL-12 and KS. IL-12 is a cytokine that enhances type 1 immunity, induces production of interferon gamma (IFN-gamma), and mediates antiangiogenic effects. In addition, it can downregulate a constitutively active G protein coupled receptor that is encoded by Kaposi's sarcoma-associated herpesvirus, the causative agent of KS. These factors suggested that IL-12 might be worth exploring as a potential anti-KS agent. In an initial phase I pilot study, IL-12 was found to have anti-KS activity when used alone in patients with AIDS-associated KS who were on a stable regimen of antiretroviral therapy. In preliminary results from a subsequent study of the combination of IL-12 plus liposomal doxorubicin along with highly active antiretroviral therapy, remissions were obtained in a substantial percentage of patients with advanced AIDS-associated KS. IL-12 has also been found active in patients with certain lymphomas. These results suggest that IL-12 may be worth exploring further as a potential antitumor agent in selected tumors.
تدمد: 2162-6472
DOI: 10.1615/critrevimmunol.v27.i5.10
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::6f4df59dd6b3c654af8f43edf3ff4208
https://doi.org/10.1615/critrevimmunol.v27.i5.10
رقم الانضمام: edsair.doi...........6f4df59dd6b3c654af8f43edf3ff4208
قاعدة البيانات: OpenAIRE
الوصف
تدمد:21626472
DOI:10.1615/critrevimmunol.v27.i5.10